Expert: Approval of Aducanumab for Alzheimer Disease 'Is a Huge Accomplishment'

Despite the controversy surrounding the FDA approval of aducanumab for patients with Alzheimer disease, Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, said this is "a huge accomplishment."

Because there are no other available treatment options, Spicer said the approval of aducanumab gives much-needed hope to patients with Alzheimer disease and their families. She added that other investigational drugs for Alzheimer disease could have encouraging results in the future, but this approval offers a more immediate treatment option.